-+ 0.00%
-+ 0.00%
-+ 0.00%

ARVINAS : PHASE 1 ARV-102 SHOWED DOSE-DEPENDENT IMPROVEMENTS IN EYE MOVEMENT IN PARKINSON'S PATIENTS

Reuters·10/07/2026 11:10:01